287 related articles for article (PubMed ID: 16900111)
1. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
2. MS drug back on market under restricted program.
FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
[No Abstract] [Full Text] [Related]
3. Tysabri risk causing headache for companies.
Sheridan C
Nat Rev Drug Discov; 2005 Sep; 4(9):703-4. PubMed ID: 16178114
[No Abstract] [Full Text] [Related]
4. Tysabri's troubles return.
Hoag H
Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
[No Abstract] [Full Text] [Related]
5. Tysabri withdrawal calls entire class into question.
Singer E
Nat Med; 2005 Apr; 11(4):359. PubMed ID: 15812500
[No Abstract] [Full Text] [Related]
6. How Tysabri survived.
Huggett B
Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
8. Balancing risk and reward: the question of natalizumab.
Hauser SL; Johnston SC
Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
[No Abstract] [Full Text] [Related]
9. [Natalizumab in multiple sclerosis].
Rajda C; Bencsik K; Vécsei L;
Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
[No Abstract] [Full Text] [Related]
10. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
11. Tysabri raises alarm bells on drug class.
Sheridan C
Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
[No Abstract] [Full Text] [Related]
12. The trials and tribulations of Tysabri.
Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
[No Abstract] [Full Text] [Related]
13. The return of natalizumab: weighing benefit against risk.
Goodin D
Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
[No Abstract] [Full Text] [Related]
14. [Treatment of multiple sclerosis].
Holmøy T; Harbo HF; Celius EG
Tidsskr Nor Laegeforen; 2010 May; 130(9):923; author reply 923. PubMed ID: 20453948
[No Abstract] [Full Text] [Related]
15. US drug approval ignores science's subtleties, experts say.
Waltz E
Nat Med; 2006 Apr; 12(4):373. PubMed ID: 16598269
[No Abstract] [Full Text] [Related]
16. MS drug withdrawn from market.
FDA Consum; 2005; 39(3):3. PubMed ID: 16127808
[No Abstract] [Full Text] [Related]
17. CD20 blockers eye crowded rheumatology market.
Mack GS
Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
[No Abstract] [Full Text] [Related]
18. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
19. Biotech jostles with pharma for slice of HIV market.
Katsnelson A
Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
[No Abstract] [Full Text] [Related]
20. Third Tysabri adverse case hits drug class.
Sheridan C
Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
[No Abstract] [Full Text] [Related]
[Next] [New Search]